U.S. markets open in 4 hours 23 minutes
  • S&P Futures

    4,366.50
    +23.25 (+0.54%)
     
  • Dow Futures

    33,980.00
    +182.00 (+0.54%)
     
  • Nasdaq Futures

    15,084.25
    +60.25 (+0.40%)
     
  • Russell 2000 Futures

    2,197.10
    +16.20 (+0.74%)
     
  • Crude Oil

    71.68
    +1.19 (+1.69%)
     
  • Gold

    1,776.40
    -1.80 (-0.10%)
     
  • Silver

    22.70
    +0.09 (+0.39%)
     
  • EUR/USD

    1.1740
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    1.3240
    0.0000 (0.00%)
     
  • Vix

    22.86
    -2.85 (-11.09%)
     
  • GBP/USD

    1.3640
    -0.0024 (-0.18%)
     
  • USD/JPY

    109.5190
    +0.2990 (+0.27%)
     
  • BTC-USD

    42,331.64
    -858.27 (-1.99%)
     
  • CMC Crypto 200

    1,055.73
    -8.12 (-0.76%)
     
  • FTSE 100

    7,057.45
    +76.47 (+1.10%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

·3 min read
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.